Gene therapy for inherited retinal degeneration from RDH12 mutations
Part of Eyes & vision clinical trials.
This trial tests an experimental gene therapy (OPGx-RDH12-1001) injected under the retina to treat a rare form of inherited vision loss called LCA caused by RDH12 gene mutations. It aims to see if the treatment is safe and tolerable for people with advanced vision loss.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 12 years or older.
- You have a vision loss condition called LCA caused by a specific genetic change (RDH12 mutation), confirmed by a blood test.
- Your vision in at least one eye is 20/200 or worse (for adults) or 20/40 or worse (for others).
- You have not had any gene therapy before.
- You are healthy enough for eye surgery and do not have active eye infections, recent eye surgery, or conditions that make surgery risky.
- Women who can get pregnant must use contraception for one year after treatment; men must use contraception for 180 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 trial tests the safety and early effectiveness of HG004 (a gene therapy) in people with Leber congenital amaurosis caused by RPE65 gene changes. It aims to see whether treating the eye can improve or stabilize vision-related measures while monitoring side effects.
This program tests an experimental gene therapy for adults with retinitis pigmentosa (RP), an inherited eye disease that causes vision loss. It aims to see if the treatment can help preserve or improve vision.
This trial tests an injection called PUMCH-E101 for people with vision loss caused by changes in the RDH12 gene. The goal is to see if it is safe and if it can help improve vision.
This trial tests a gene therapy injection into the eye to improve vision in people with a specific type of inherited optic nerve disease called Leber’s hereditary optic neuropathy (LHON). It is aimed at people who have a particular genetic change and a history of vision loss lasting long enough to measure change, while checking for safety first.
This trial tests a gene therapy called GS010 given as an injection into the eye for people with vision loss from LHON. It aims to see if it can help improve vision in both eyes.
This trial tests two doses of a gene therapy (AGTC-501) in males who already had one eye treated with a similar gene therapy for X-linked retinitis pigmentosa caused by RPGR mutations. The goal is to see if the treatment is safe and can help preserve or improve vision.
Hear when a new Leber Congenital Amaurosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.